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PTTG2 silencing results in induction of
epithelial-to-mesenchymal transition and apoptosis
C Me´ndez-Vidal1,2,3, M del Mar Ga´mez-Del Estal1,3, MA Moreno-Mateos1, A´G Espina-Zambrano1, B Torres1 and JA Pintor-Toro*,1
Human securin, also known as human pituitary tumor-transforming gene 1 (pttg1), plays a key role in cell-cycle regulation.
Two homologous genes, pttg2 and pttg3, have been identified although very little is known about their physiological function.
In this study, we aimed at the characterization of these two pttg1 homologs. Real-time PCR analysis using specific probes
demonstrated that Pttg2 is expressed at very low levels in various cell lines and tissues whereas Pttg3 was largely undetectable.
We focused on the study of Pttg2 and found that, unlike PTTG1, PTTG2 lacks transactivation activity and does not bind to
separase, making improbable a role in the control of sister chromatids separation. To further investigate the biological
role of pttg2, we used short hairpin RNA inhibition of Pttg2 and found that cells with reduced Pttg2 levels assumed a rounded
morphology compatible with a defect in cell adhesion and died by apoptosis in a p53- and p21-dependent manner. Using
microarray technology, we generated a gene expression profile of Pttg2-depleted cells versus wild-type cells and found that
knockdown of PTTG2 results in concomitant downregulation of E-cadherin and elevated vimentin levels, consistent with EMT
induction. The observation of aberrant cellular behaviors in Pttg2-silenced cells reveals functions for pttg2 in cell adhesion and
provides insights into a potential role in cell invasion.
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The securin family of proteins play a key role in the regulation
of sister chromatids separation during mitosis.1 These
proteins have been identified in Drosophila (Pimples
proteins), fission yeast (CUT2), budding yeast (PDS1) and
vertebrates (Securin/Pttg1). In addition to its role during
mitosis, PTTG1 has the capacity to transform murine
fibroblasts in vitro, it promotes tumor formation in athymic
mice and it is abundantly expressed in different cancer cell
lines and tumors, including pituitary adenomas, primary
epithelial neoplasms and hematopoietic malignancies.2
Human securin prevents premature chromosome segre-
gation through the inhibition of separase, a protease that
cleaves cohesin, which links sister chromatids.3 Deregulated
securin may thereby result in chromosome missegregation
leading to an increase in proto-oncogene dose or to loss of
heterozygocity of tumor suppressors.4 The pttg1 gene locates
at chromosome 5q33 and consists of five introns and six
exons. In higher mammals, two homologous intronless genes,
pttg2 and pttg3, which are located on chromosomes 4p12 and
8q13, respectively, have been reported.5,6 The homology
between the three genes is very high, being PTTG1 89%
identical to PTTG3 and 91% identical to PTTG2, although
PTTG2 and PTTG3 are only 84% identical at the amino-acid
level. PTTG2 and PTTG3 contain several conserved motifs
present in PTTG1 including two proline-rich domains at the
C-terminus, suggesting that these genes might mediate
their functions through the interaction with other proteins.
In addition, the destruction box present in PTTG17 is also
conserved in both proteins but not the KEN box in the case
of PTTG2, which could affect the stability of this protein.
RT-PCR studies have shown that Pttg1 is the most abundant
and mainly expressed in normal adult testis and thymus.8
Pttg2mRNA is expressed at low levels in various cell lines and
in normal and tumor tissues.5,6 In contrast, the expression of
Pttg3 by northern blotting revealed no expression of Pttg3 in
human tissues. In fact, pttg3 has been recently classified as a
pseudogene in different studies.9
Epithelial-to-mesenchymal transition (EMT) is a key event
in embryonic morphogenesis involving the expression
of several EMT-associated genes. In addition, EMT occurs
during the progression of some human cancer providing
motility and invasiveness to cancer cells.10,11 EMT-inducing
genes with essential roles in EMT include twist,12 zeb1,13 or
snail/slug.14,15 These genes function as direct (snail/slug and
zeb1) or indirect (twist) transcriptional repressors of E-cad-
herin whose functional loss is one of the hallmarks of EMT.
Other changes associated to EMT include loss of cell–cell
adhesion, altered polarity, rearrangement of cytoskeletal
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proteins (intermediate filaments revert from keratins to
vimentin) and resistance to cell death-induced by loss of
cellular attachment (anoikis).
Given the lack of studies of Pttg2, we sought to complete a
detailed characterization of this gene in order to reveal its
putative cellular functions. We found that depletion of PTTG2
led to cell rounding followed by p53- and p21-dependent
apoptosis. Also, we observed that the lack of PTTG2 results in
low E-cadherin and high vimentin levels, which are associated
with the induction of EMT. This work reveals novel aspects of
Pttg2 and attributes an important role for Pttg2 in cell adhesion
and EMT induction.
Results
Characterization of Pttg2-silenced HCT116 cells. pttg1
shares high-sequence homology with the intronless genes,
pttg2 and pttg3 of unknown biological functions. To dissect
the cellular function of each isoform, we aimed to search for
specific shRNAs against Pttg1, Pttg2 and Pttg3. However,
during the course of this study, pttg3 was classified
as a pseudogene (http://www.ncbi.nlm.nih.gov/nuccore/NR_
002734.1) and therefore, excluded from this study. Impor-
tantly, pttg3 was also disqualified as a coding gene from the
Intronless Genes Database (http://www.bioinfo-cbs.org).
For this reason, here we focused on the characterization of
the pttg2 gene. To find the most efficient and specific shRNA
against Pttg2, we tested the capacity of five different shRNA
lentiviral clones (Sigma, St. Louis, MO, USA), located at
different regions within Pttg2 ORF, to reduce Pttg2 levels.
Unfortunately, none of them (including a duplex siRNA
containing five mismatches compared with Pttg1) were able
to specifically silence Pttg2 without altering Pttg1 mRNA
levels. Based on these results, we selected the shRNAs for
Pttg1 (shPttg1) and Pttg2 (shPttg2) shown in Figure 1a, both
containing two mismatches. Pttg2 mRNA levels were
reduced by 62% or 35% using shPttg2 and shPttg1,
respectively, while Pttg1 was reduced 65% by shPttg2 and
90% by shPttg1 (Figure 1b). A similar reduction in Pttg2
levels was observed in the absence of Pttg1 as determined
by qPCR using HCT116 pttg1 / cells (Figure 1b). The
reduction of PTTG1 and PTTG2 at the protein level was
checked by immunoblotting using extracts of HCT116 cells







































Figure 1 Characterization of Pttg2-depleted HCT116 cells. (a) Schematic diagram showing the sequences and location of shPttg1 and shPttg2. Multiple sequence
alignments were made using the Clustal W software (www.clustal.org). (b) Relative quantification of Pttg1 and Pttg2 mRNA levels in Pttg1 and Pttg2-silenced HCT116 wild-
type and HCT116 pttg1 / cells by real-time PCR. Expression of each gene is shown as mean±S.E.M. of three independent experiments. Data are shown as 2DCT
normalized to HPRT1. (c) Analysis of PTTG1 and PTTG2 protein levels 72 h after shRNA-Pttg1 or shRNA-Pttg2 treatment in HCT116 wild-type and HCT116 pttg1 / cells.
b-Actin was used as loading control. Densitometric analysis for western blots of PTTG1 and PTTG2 protein expression (% of control) in control and shRNA-treated (shPttg1 or
shPttg2) wild-type and Pttg1 / HCT116 cells
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vector and specific PTTG1 and PTTG2 antibodies
(Figure 1c, left panel). As observed, the reduction of both
proteins at the protein level was consistent with the reduction
of the mRNA levels shown in Figure 1b. Similarly, a decrease
of PTTG2 levels in the HCT116 pttg1 / cell line was
detected (Figure 1c). Here, it should be noted, the low
PTTG2 expression levels compared with PTTG1. This is not
due to antibody sensitivity since three different PTTG2
antibodies raised against GST and His-tagged proteins or a
synthetic peptide located at the C-terminal region of PTTG2,
were used. This made unfeasible to routinely check
PTTG2 protein levels during the study. Also, similar levels
of Pttg2 mRNA expression were found in cells of different
origin including human embryonic kidney HEK293T cells,
hTERT-immortalized retinal pigment epithelial cell line RPE1,
human breast adenocarcinoma MCF7 cells and the cervical
cancer cell line HeLa (data not shown). In addition, low levels
of Pttg2 were found in numerous human tissues as
ascertained by normal tissue cDNA arrays (TissueScan,
Origene, Rockville, MD, USA) and Pttg2-specific Taqman
probes (Supplementary Figure S1).
Pttg2 and Pttg1 show different biochemical properties.
The high-sequence homology between Pttg1 and Pttg2
prompted us to test whether, similarly to Pttg1, Pttg2 could
also regulate sister chromatid separation through binding to
separase. We performed immunoprecipitation assays in
HEK293T cells using C-terminal Myc-tagged PTTG2
and N-terminal FLAG-tagged separase and found that
Pttg2 lacks the ability to interact with separase under the
experimental conditions used (Figure 2a, upper panel). As a
control, we show binding of PTTG1 to separase (Figure 2a,
lower panel).16 This indicates that likely PTTG2 does not play
a role in preventing premature chromatids separation,
at least not through the interaction with separase. Moreover,
we investigated the transactivation capacity of PTTG2,
which represents another important feature of PTTG1. We
generated fusions of GAL4-DNA-binding domain with full-
length PTTG2 as well as with the VP16 transactivation
domain and tested them in HEK293T cells for activation of
transcription from a luciferase reporter construct. The results
showed no significant increase of reporter gene activity by
GAL4-PTTG2 over the background, confirming the lack of
transcriptional activity (Figure 2b). As positive controls, we
used GAL4-VP16 and GAL4-PTTG1 previously reported to
upregulate luciferase reporter activity.8 Altogether, these
results indicate that most likely, PTTG1 and PTTG2
participate in different biological responses.
Silencing of Pttg2 impairs normal cell adhesion, reduces
cell proliferation and promotes apoptosis in HCT116
cells. To elucidate Pttg2 function, we made use of the RNAi
technology and infected HCT116 with lentiviral particles
expressing the Pttg2 shRNA described in Figure 1a. As
depicted in Figure 3a, the shape of Pttg2-depleted cells was
rounder compared with control cells, morphology compatible
with an apparent loss of cell adhesion. Importantly, the
same phenotype was reproduced in human embryonic
kidney HEK293T cells, indicating that this effect is a
general property of Pttg2 downregulation (Supplementary
Figure S2c). To study the adhesion capacity of these cells
under anchorage-independent conditions, we transferred
mock-infected cells and cells infected with shPttg2 onto
poly-HEMA-coated plates. Poly-HEMA is known to prevent
cell–matrix interactions while preserving cell–cell contacts.
Under these conditions, control cells formed dense spher-
oidal aggregates while shPttg2-infected cells appeared more
dispersed and formed only loose clumps of cells (Figure 3b,
middle panel), indicating that the cell–cell interconnection is
Figure 2 Pttg1 and Pttg2 show different biochemical properties. (a) PTTG2
does not interact with Separase. Extracts of HEK293T cells expressing N-terminally
Flag-tagged separase, C-terminally Myc-tagged PTTG2, or both were used for
immunoprecipitation with anti-Myc antibodies. The immunoprecipitates were
analyzed by immunoblotting with anti-FLAG and anti-Myc antibodies. The asterisks
indicate the immunoglobulin light chains. As positive control, the interaction between
PTTG1 and separase was tested using Flag-separase and Myc-tagged PTTG1.
(b) PTTG2 lacks transactivation capacity. The ORF of Pttg2 was fused to the GAL4
DNA-binding domain (pGAL4-DBD-Pttg2) and tested for transcription activation in
HEK293T cells cotransfected with a GAL4 site-dependent reporter plasmid driving
expression of the luciferase gene (pGAL4-4RE-Luc). pGAL4-PTTG1 and pGAL4-
VP16 were used as positive controls. Luciferase values from at least three
independent transfections are plotted as fold activation over control
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compromised. Given that the treatment with shPttg2 also
results in a reduction of PTTG1 levels, we analyzed the
morphology of cells with reduced PTTG1 levels (shPttg1-
treated) growing on poly-HEMA plates. As shown in Figure 3,
these cells formed dense typical round colonies with tightly
associated cell–cell contacts similarly to control cells
(Figure 3b, lower panel). This suggests that the observed
phenotype is mainly due to PTTG2 deficiency. Further, when
the proliferation of cells with diminished PTTG2 levels was
measured, we found that Pttg2-depleted cells showed
reduced BrdU incorporation (37%) and mitotic index
(55% of nocodazole-treated cells) compared with control
Figure 3 Silencing of Pttg2 impairs cell adhesion and proliferative capacity of HCT116 cells. (a) Phase-contrast images (10 objective) of Pttg2-silenced HCT116 cells
72 h (upper panels) and 1 week post-infection (PI) (lower panels). Inserts show close-up views of representative cell culture areas. Pttg2-depleted cells show rounder
morphology than control cells, indicating a defect in cell adhesion properties. (b) Spheroid formation of Pttg2 and Pttg1-silenced HCT116 (wt) cells in suspension. Seventy-two
hours post-infection, cells were transferred to poly-HEMA-coated plates at 6 104 cells/ml. After 48 h in suspension, cells were photographed at 10 . Control and shPttg1-
treated cells formed dense spheroids whereas shPttg2-silenced cells adhere to each other very weakly. Representative areas of each culture were selected. (c) Percentage of
BrdU-positive cells after shRNA-Pttg2 treatment. HCT116 cells were infected and assayed for BrdU incorporation 72 h post-infection. Bars represent the mean±S.E.M.
(d) Analysis of mitotic index in Pttg2-depleted HCT116 cells. Cells were treated with shRNA-Pttg2 lentivirus and incubated with nocodazole 1mM 72 h post-infection, for 24 h.
Percentage of H3P-positive (mitotic) cells was measured by flow cytometry. Bars represent the mean±S.E.M. (e) Percentage of cell death following shRNA Pttg2 or shRNA
Pttg1 treatment of HCT116 cells growing under adherent or suspension conditions. Seventy-two hours post-infection, cells were transferred onto control or poly-HEMA-coated
(PH) plates in the absence or presence of methylcellulose (MC) and the levels of apoptosis was determined 48 h later by measuring the percentage of cells containing a subG1
DNA content by flow cytometry. Results represent the means of three independent experiments±S.E.M. (f) p21 induction in Pttg2-depleted HCT116 cells. HCT116 cells
treated with shRNA-Pttg2 lentivirus for 72 h were harvested and the levels of p21 determined by immunoblotting using specific p21 antibodies. b-Actin was used as loading
control
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cells (Figures 3c and d, respectively), indicating that in our
cells, the loss of cellular adherence is accompanied by
reduced proliferative capacity.
Notably, we observed that cell aggregation in suspension
promoted cell survival while loss of adhesion of shPttg2-
treated cells was followed by increased cell death (20–30%)
as measured by the number of cells presenting fragmented
DNA (subG1 peak) (Figure 3e). To reinforce the results
indicating that downregulation of Pttg2 and not Pttg1 cause
induction of apoptosis in HCT116 cells, we measured
the apoptotic response of Pttg2-silenced cells in which
Pttg1 levels have been restored by ectopic expression of
Pttg1 cDNA. As shown in Supplementary Figure S3, Pttg1
was restored to levels similar as those observed in control
cells while maintaining low Pttg2 levels (Supplementary
Figure S3a). In this scenario, analysis of the apoptotic
response in these cells showed that restoration of Pttg1
levels in Pttg2-silenced cells does not rescue the apoptotic
phenotype (Supplementary Figure S3b). In addition, a similar
apoptotic response was observed in HEK293T cells treated
with shPttg2 (Supplementary Figures S2b and c) that
specifically resulted in Pttg2 downregulation while leaving
Pttg1 levels unaltered (Supplementary Figure S2a). Collec-
tively, these data reinforce the idea that Pttg2 is an important
regulator of apoptosis in both cell types.
As a control of the importance of cell aggregation in cell
survival of HCT116 cells, we used poly-HEMA-coated plates
and methylcellulose in the culture medium to minimize
cell–cell contacts in suspension. As expected, cell aggregates
were not formed in the methylcellulose suspension cultures
(data not shown) in both control and Pttg2-depleted cells,
resulting in augmented cell death in control cells at levels
similar to Pttg2-depleted cells under all conditions. This
indicates that the leading cause of death in Pttg2-depleted
cells is the loss of cell adhesion.
As mentioned above, Pttg2 shRNA led to the reduction of
both PTTG1 and PTTG2 levels. To clarify the role of Pttg1
depletion in the cell death seen in Pttg2-silenced HCT116
cells, we determined the cell-cycle profile of cells separately
treated with shPttg1 or shPttg2 (Figure 3e). As shown, a
reduction of Pttg1 mRNA levels (by 90%, data not shown)
without a concomitant reduction of Pttg2 did not result in an
increase in the number of dead cells. Consistent with
earlier reports, we conclude that cell–cell adhesions under
anchorage-independent conditions are crucial for the survival
of HCT116 cells and confirm the important role that Pttg2
plays in the maintenance of cellular adhesion.
In order to characterize in detail the observed lack of
adhesion phenotype, we examined the expression levels of
p21, a protein previously reported to be upregulated under
these conditions.17,18 In fact, loss of adhesion following Pttg2
silencing in HCT116 cells was accompanied by an increase in
p21 (Figure 3f). Similarly, Pttg2 silencing resulted in increased
p21 levels in HCT116whereas depletion of Pttg1 in these cells
did not affect p21 protein levels (Supplementary Figure S4).
These results further confirmed a defective cell adhesion
phenotype in cells with reduced Pttg2 levels.
Pttg2-depleted cells die from p53- and p21-dependent
apoptosis. To further characterize the observed
adhesion-dependent cell death, we tested the effect of the
addition of the caspase inhibitor z-VAD to the cell media of
control and Pttg2-silenced cells growing under adherent
conditions. As depicted in Figure 4a, the cell death
phenotype observed in shPttg2-treated cells, was partially
reverted in the presence of z-VAD. In agreement, the number
of dead cells after PTTG2 silencing was drastically reduced
(Figure 4b), suggesting that cells lacking Pttg2 eventually
die through caspase-dependent apoptosis following cell
rounding, a phenomenon also known as anoikis. In addition,
western blot analysis of extracts from HCT116 cells treated
with shPttg2 displayed elevated p53 protein (Figure 4c,
upper panel), as well as the apoptosis indicator active
caspase-3 (Figure 4c, lower panel) or the detachment-
induced pro-apoptotic factor Bim (Figure 4c, middle panel),
reported to undergo alternative splicing to generate three
variants: BimEL, BimL and BimS.19 To further analyze the
role of p53 in Pttg2-dependent anoikis, we used HCT116
p53 / cells infected with control lentivirus or lentivirus
expressing shPttg2. The absence of p53 in shPttg2-treated
cells decreased the extent of anoikis morphology (Figure 4d)
and led to reduce number of apoptotic cells compared with
shPttg2-treated wild-type cells (Figure 4e).
As mentioned before, loss of cell adhesion led to the
concomitant induction of p21 in a p53-dependent manner as
cells lacking p53 and treated with shPttg2 did not present a
significant increase in p21 levels (Figure 4f). In addition to its
function as a cell-cycle regulator, a role in apoptosis has
been attributed to p21.20,21 To study the contribution of p21 to
shPttg2-mediated apoptosis, we used HCT116 p21 / cells
and our shRNA against Pttg2. Infection of shPttg2 did not
cause cell death in p21-deleted HCT116 human colon
carcinoma cells (Figure 4g). These results indicate that
reduced Pttg2 levels induce inhibition of cell growth through
p53-dependent p21 induction, and p21 appears to be a critical
effector of shPttg2-induced cell death. Taken together, these
results extend previous studies showing that the disruption of
cell–matrix interactions in murine cells activates the p53–p21
pathway.18
We asked further if the observed loss of cell adhesion
precedes the onset of apoptosis. To this purpose, we used
shPttg2-treated cells growing on poly-HEMA-coated plates
and treated with z-VAD. As displayed in Figure 5a, the loss of
adhesion phenotype of shPttg2-silenced cells was also found
in the presence of z-VAD. Despite this, we observed reduced
number of dead cells, indicating an apoptotic effect due to loss
of appropriate adhesion (Figure 5b). The same effect
was observed in HCT116 p53 / cells expressing shPttg2
(Figures 5c and d).
Pttg2 expression is required for normal tubulin
distribution. To test if the altered cellular morphology could
be a consequence of cytoskeletal defects, we analyzed
a-tubulin distribution by immunostaining in HCT116 cells
infected with control lentivirus or lentivirus expressing Pttg2
shRNA. As shown in Figure 6, Pttg2-depleted cells showed
an altered pattern of a-tubulin compared with control cells,
suggesting that the reduced intercellular adhesions of Pttg2-
depleted cells are coupled with abnormal distribution of
cytoskeletal proteins such as a-tubulin. In addition, the levels
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of acetylated a-tubulin were elevated in shPttg2-depleted
cells as ascertained by western blot (data not shown)
indicative of impaired microtubules dynamics in cells with
reduced Pttg2 levels.
PTTG2 regulates E-cadherin and vimentin levels leading
to EMT induction. To elucidate the mechanisms by which
Pttg2 regulates cell adhesion, we analyzed the gene
expression profiles of cells depleted of Pttg2 compared with
wild-type cells. Of the 28869 genes represented on the
GeneChip Human Gene 1.0 ST array, 439 genes were
identified to be differentially expressed, with a significance
Po0.01 and fold change 41.5 (Supplementary Table S2).
Some examples of differentially regulated genes classified by
fold change or biological interest have been listed in Table 1.
Functional analysis of the 157 upregulated (138 annotated
Figure 4 Defective adhesion in Pttg2-depleted HCT116 cells results in p53- and p21-dependent apoptosis. (a) Phase-contrast images of Pttg2-silenced HCT116 cells
after z-VAD treatment. A round morphology was still observed in Pttg2-depleted cells, suggesting a defective cell adhesion. (b) Apoptosis can be rescued in Pttg2-silenced
HCT116 cells after caspase inhibition treatment. The percentage of apoptotic cells (subG1) after PTTG2 depletion was drastically reduced after treatment with the caspase
inhibitor z-VAD. Bars represent the mean±S.E.M. (c) Levels of apoptotic indicators in Pttg2-silenced HCT116 cells. Cells were harvested after 72 h post-infection and
assayed for p53, p21, BIM and cleaved-Capase 3 levels by western blot using specific antibodies. b-Actin was used as loading control. (d, e) Role of p53 in Pttg2-dependent
anoikis. (d) Phase-contrast images of Pttg2-depleted HCT116 p53 / cells. The absence of PTTG2 in HCT116 p53 / results in cell rounding similar to wild-type HCT116
cells. (e) FACS analysis of Pttg2-depleted HCT116 p53 / cells. In the absence of PTTG2, the percentage of apoptotic cells (subG1) was partially reduced in
HCT116 p53 / cells compared with HCT116 wild-type cells. Bars represent the mean±S.E.M. (f) The induction of p21 in Pttg2-treated cells occurs in a p53-dependent
manner. Western blot analysis of p21 levels in HCT116 p53 / cells 72 h post-infection with shPttg2 or control lentivirus. b-Actin was used as loading control. (g) Role of p21
in anoikis in Pttg2-depleted cells. The percentage of apoptotic cells in HCT116 p21 / following treatment with shPttg2 was significantly reduced compared with HCT116
wild-type cells. Bars represent the mean±S.E.M.
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genes) and 323 downregulated probes (301 annotated
genes) was performed using DAVID program (david.abcc.
ncifcrf.gov). As revealed by the Gene Ontology (GO), among
the upregulated probes, genes involved in apoptosis, protein
kinase activity and related to the control of the extracellular
space were specifically activated by Pttg2 downregulation
(Figure 7a; Table 1). On the other hand, of the down-
regulated 323 probes, genes involved in cell cycle, nucleotide
binding and to intracellular non-membrane-bounded orga-
nelles were particularly downregulated by shPttg2 treatment.
Figure 5 Loss of cell adhesion in shPttg2-treated cells precedes the onset of apoptosis. (a) Spheroid formation of Pttg2-depleted cells after z-VAD treatment. Wild-type
HCT116 cells were infected for 72 h in the presence or absence of the caspases inhibitor z-VAD and the cell–cell adhesion capacity assayed on poly-HEMA (PH)-coated
plates. The experiments were repeated three times, and representative areas of each culture are shown. (b) Cell-cycle profile of Pttg2-silenced HCT116 cells growing under
poly-HEMA conditions after z-VAD treatment. The percentage of apoptotic cells (subG1) was significantly reduced in the presence of z-VAD, whereas the other cell-cycle
phases (G1, S and G2/M) were not modified. Data are representative of two independent experiments. (c) Phase-contrast images to assess multicellular aggregates formation
in shPttg2-treated HCT116 p53 / cells growing on poly-HEMA-coated plates. Images show a representative region of each condition. (d) Analysis of the cell-cycle
profile of Pttg2-depleted HCT116 p53 / cells growing under poly-HEMA conditions. ShPttg2-treated cells lacking p53 showed a reduced percentage of cell death (subG1).
The other cell-cycle phases (G1, S and G2/M) remained unaltered. Data are representative of two independent experiments
Figure 6 Pttg2-depleted cells exhibit cytoskeletal defects. Microtubule cytoskeleton of PTTG2 depleted cells. Confocal images of Pttg2-silenced HCT116 cells stably
expressing Histone H2B (H2B)-cherry fusion gene. Seventy-two hours post-infection, cells were fixed with methanol at  20 1C and stained for a-tubulin (green). Scale bars,
25mm
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Remarkably, consistent with our phenotypic observations,
among the differentially expressed genes we found two
previously reported genes, p21 and Bim, known to be
upregulated following cell detachment. As previously shown
in Figures 3f and c, we also found increased p21 and Bim
levels following Pttg2 knockdown, which further validate our
array data. Also, because of the impaired cell adhesion
phenotype of shPttg2 cells, we chose to examine E-cadherin,
another differentially regulated gene that showed 1.49-fold
decrease in cells with low Pttg2 levels. To enhance the
significance of the array analysis, the mRNA data of
E-cadherin was validated by real-time PCR and the respective
protein analyzed by western blot. As displayed in Figure 7b,
quantitative PCR analysis showed a reduction of 40% in
E-cadherin mRNA levels after shPttg2 transfection. Also,
E-cadherin protein levels were reduced in cells with reduced
PTTG2 levels (Figure 7c). Otherwise, it has been shown that
in HCT116 cells, the amount of E-cadherin protein was
strongly increased when cells were transferred from mono-
layer to suspension culture over a period of 48 h.22 Notably,
Pttg2-depleted cells presented lower levels of E-cadherin
when growing under non-adherent conditions on poly-HEMA-
coated plates compared with control cells growing under
similar conditions (Figure 7c).
Next, given the round morphology and the low E-cadherin
levels of cells with reduced Pttg2 levels, we explored the
association between lack of adhesion of shPttg2 cells and
EMT induction. For this purpose, we chose to examine the
levels of vimentin, another mesenchymal phenotypic marker.
Both the array data and real-time PCR experiments showed
that the loss of E-cadherin correlated with a significant
increase in vimentin mRNA levels (1.87-fold-induction in the
arrays experiments and 2.55-fold-induction in quantitative
PCR analysis) (Figure 7d). In conclusion, our data show a
phenotype resembling EMT, characterized by repression of
E-cadherin and increased vimentin expression. Interestingly,
the main features of this phenotype were independent of p53
and p21 status as cells lacking these genes and treated with
shPttg2 also adopted EMT features including spindle-like cell
morphology (Figure 4d and data not shown), loss of the
epithelial cellular marker E-cadherin (data not shown) and
increased survival (Figures 4e and g).
Discussion
The pttg2 gene shares high-sequence homology with
pttg1/securin. However, to date, no studies have been
conducted to elucidate the biological role of this poorly
understood securin family member. Here, we partially char-
acterize Pttg2 and found that it has other activities different
from Pttg1, among which we highlight a novel role in cellular
adherence and induction of epithelial–mesenchymal transi-
tion, presumably through the regulation of E-cadherin levels.
pttg2 is a single exonic gene. Initially, the loss of introns was
associated with the origin of processed pseudogenes.
However, more recently, it has been demonstrated that some
of them have acquired upstream regulatory elements and
become functional (retrogenes).23,24 It has been suggested
that introns may contain signals to stabilize transcription or
retard regulatory responses. We found that Pttg2 is minimally
expressed in normal cells. This is in agreement with the fact
that intronless genes are tipically expressed at significantly
lower levels and in a narrower range of tissues than spliced
genes with the exception of histones.25
In this study, we have compared the biochemical properties
of PTTG1 and PTTG2. We first tested whether PTTG2 could
also bind to separase. Under our experimental conditions,
PTTG2 was unable to bind separase, a prerequisite to
function as a securin. The binding site of PTTG1 to separase
has been mapped to the N- and C-terminal regions.
Importantly, these motifs are not conserved in PTTG2,
explaining why PTTG2 failed to interact with separase.
Similarly, PTTG2 did not exhibit detectable transactivation






Interferon-induced protein with tetratricopeptide repeats 1 IFIT1 NM_001548 5.27 Cell proliferation
Vimentin VIM NM_003380 1.86 Cell adhesion
Cyclin-dependent kinase inhibitor 1A p21 NM_078467 1.79 Cell cycle
Bcl2-like 11 BCL2L11
(Bim)
NM_138621 1.64 Induction of apoptosis
by extracellular signals
Bcl2-antagonist/killer 1 BAK1 NM_001188 1.64 Apoptosis
Fas (TNF receptor superfamily member 6) FAS NM_000043 1.62 Apoptosis
Homo sapiens zinc-finger E-box binding homeobox 1 (ZEB1),
transcript variant 2
ZEB1 NM_030751 1.39 Cell adhesion
Homo sapiens snail homolog 1 SNAI1 NM_005985 1.33 Cell adhesion
Homo sapiens fibronectin 1 FN1 NM_212482 0.77 Cell adhesion substrate
adhesion-dependent cell
spreading
Homo sapiens cadherin 1, type 1, E-cadherin (epithelial) CDH1 NM_004360 0.67 Cell adhesion cell–cell
adherens junction
microRNA 21 MIR21 NR_029493 0.54 Cell migration
Homo sapiens integrin, a V (vitronectin receptor,
a polypeptide, antigen CD51) (ITGAV),
transcript variant 1, mRNA
ITGAV NM_002210 0.47 Cell adhesion cell–matrix
adhesion
Pituitary tumor-transforming gene 1 PTTG1 NM_004219 0.43 Cell cycle
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function. These results revealed that most likely PTTG1 and
PTTG2 play distinct cellular roles.
Through our characterization of HCT116 cells depleted of
Pttg2, we demonstrate that the absence of Pttg2 results in
morphologic changes consistent with loss of adherence and
cell death by apoptosis. Although we cannot unequivocally
attribute this effect to the lack of Pttg2 alone, several
evidences indicate that Pttg2 depletion specifically induces
cell death by loss of anchorage. First, a clear induction of the
apoptotic response has been observed in shPttg2-treated
HEK293T cells showing a more specific depletion of Pttg2
than HCT116 cells treated in the same way. Furthermore,
HCT116 depleted of Pttg2 but expressing Pttg1 at similar
levels as untreated cells, showed comparable levels of
apoptosis with respect to cells displaying a concomitant
reduction of Pttg2 and Pttg1 levels. Moreover, our data
indicate that, under the experimental conditions used, Pttg1
deficiency alone does not affect cell survival. This has been
further supported by a recent study showing unaltered cell
survival following siRNA Pttg1 treatment in HCT116 wild-type
cells.26 In addition, homozygous loss of pttg1 is not lethal to
human cells.4 Given that the lack of Pttg1 results in no obvious
Figure 7 Pttg2 depletion results in deregulated E-cadherin and vimentin levels and induction of the epithelial-to-mesenchymal transition. (a) Summary of gene expression
profile according to Gene Ontology. Pie charts show the percentage of genes included in each category (molecular function, biological process and cellular component) and
subcategories with a P-valueo0.01. The GO analysis was performed using DAVID v.6.7 program. GO analysis of differentially upregulated or downregulated genes are
shown in upper and lower panels, respectively. (b) Validation of E-Cadherin downregulation in Pttg2-silenced cells by quantitative PCR. HCT116 cells were infected with
shPttg2 or control lentivirus and assayed for E-cadherin mRNA levels 72 h post-infection. Values were normalized using the hprt1 gene as an internal control. Columns
represent the mean values of 2–3 independent experiments±S.E.M. (c) Western blot analysis of E-Cadherin repression in Pttg2-depleted HCT116 cells. The expression
levels of the E-Cadherin protein in shPttg2 cells was compared with control cells expressing an empty lentiviral plasmid. Cells were grown either as a monolayer (attached) or in
suspension for 48 h on poly-HEMA-coated plates (þPH) and total lysates analyzed by immunoblotting. (d) Vimentin mRNA induction in shPttg2-treated cells. HCT116 cells
were infected with shPttg2 or control lentivirus and assayed for vimentin levels 72 h post-infection by quantitative PCR. Values were normalized using the hprt1 gene as an
internal control. Columns represent the mean values of 2–3 independent experiments±S.E.M.
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lack of adhesion phenotype, it appears more likely, that these
changes are, in fact, the result of decreased PTTG2 level. In
fact, recent evidences suggest a role for PTTG1 in the
induction of EMT.27,28 Overexpression of PTTG1 results in
decreased E-cadherin and increased vimentin and integrin
a-V levels as well as impaired integrin-mediated focal
adhesion complexes and actin cytoskeletal reorganization.
Interestingly, the lack of Pttg2 result in morphological changes
resembling those appeared in the presence of elevated
PTTG1 levels. Although pull down experiments suggest that
Pttg1 and Pttg2 do not interact (unpublished results),
whether or not the two proteins account for the observed
morphological changes leading to EMT in our cells remains to
be determined.
Although a large number of shPttg2-treated cells presented
a mesenchymal morphology and proliferated at a normal rate,
20–30% of cells underwent apoptosis 3 days following
shPttg2 treatment. Most importantly, the number of dead
cells following Pttg2 depletion was significantly reduced in
cells harboring a homozygous deletion of the p53 or p21 gene,
indicating the absolute requirement of these genes during
shPttg2-induced cell death. Several studies have suggested
that p21 may promote apoptosis under certain cellular
stresses through both p53-dependent and p53-independent
mechanisms although exactly how p21 participates in the
apoptotic process is not clear.20 Therefore, we conclude that
low Pttg2 levels sensitize cells to anoikis and we attribute this
response to the lack of proper adhesion and the activation
of wild-type p53.
Pttg2-depleted cells displayed loss of cell–cell contacts,
which was accompanied by cell rounding andmany prominent
elongated spindle-shaped cells. In addition, a decrease of the
epithelial marker E-cadherin and increased vimentin levels
supported EMT induction. Moreover, the array data indicated
that cells with decreased Pttg2 levels also exhibit higher
levels of the E-cadherin repressors, Snail and Zeb1 (1.33 and
1.39-fold-induction in the arrays experiments, respectively)
(Table 1; Supplementary Table S2) although it is not clear
whether PTTG2 may regulate E-cadherin through the
induction of these transcription factors. In summary, even
under EMT inhibitory conditions such as Pttg1 downregulation28
and p5310,29–32 and p21 induction,10 we found that cells with low
Pttg2 levels displayed EMT markers. Altogether, these results
suggest that Pttg2 is involved in the repression of EMT.
To our knowledge, no studies have been previously
conducted to characterize Pttg2. Our results establish for
the first time an unexpected role for Pttg2 in EMT induction.
Further, epithelial cells, which undergo EMT are known to
acquire enhanced invasiveness. This raises the possibility of a
potential implication of Pttg2 in cell invasion. Further studies
are needed to determine whether the lack of this protein may
contribute to cancer cell motility under specific genetic
backgrounds that permit the survival of cells with defective
adhesion properties.
Materials and Methods
Cell culture and transfections. The HCT116 human colon carcinoma cell
line and the derivative cell lines, HCT116 Pttg1 / ,4 HCT116 p53 / 33 and
HCT116 p21 / ,34 were kindly provided by B Vogelstein (The John Hopkins
Oncology Center). HCT116 cells stably expressing H2B-mCherry were obtained
by transfection of these cells with the pcDNA3-H2B-mCherry (Addgene plasmid
20972)35 expression plasmid using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) and antibiotic selection of G418-resistant clones (1mg/ml). The HCT116 cell
lines were grown in McCoy’s medium (Sigma) supplemented with 10% heat-
inactivated fetal calf serum (Sigma) and 2mM L-glutamine, 100 U of penicillin/ml
and 100mg of streptomycin/ml (Sigma) in a 5% CO2 humidified atmosphere at
37 1C. HEK293T cells were grown in Dulbecco’s Modified Eagle medium (Sigma)
under the same conditions as HCT116 cells.
Cell adhesion assays. For cell-adhesion assays, six-well plates were
coated twice with 12mg/ml poly-HEMA (poly(2-hydroxyethyl methacrylate)
(Sigma) in 95% ethanol and dried overnight at 37 1C. Poly-HEMA-coated plates
were washed twice with PBS before seeding cells. HCT116 cells infected with
control or shPttg2lentivirus for 72 h were seeded onto poly-HEMA-coated or not
coated six-well plates at a density of 6 104 cells/ml (final volume: 3 ml/per well)
for 48 h. As a control, cells were suspended in complete growth medium
containing 2% Methylcellulose (Sigma) and plated at the same density onto
poly-HEMA-coated six-well plates for 48 h.
Lentiviral production and infection. For the generation of lentiviral
particles expressing a shRNA against Pttg1, the HIV packaging (pCMVDR8.91)
and VSVG (pMDG) plasmids and the lentiviral vector pHRSIN-DUAL-GFP (also
known as pHRSIN-CSGWdINotI_pUb_Em)36 were kindly provided by Mary
K Collins (Windeyer Institute, London). For Pttg2 silencing experiments, a set of
five MISSION TRC shRNA clones were purchased from Sigma. The different
clones were assessed for Pttg2 silencing efficiency by qPCR analysis and one
clone (TRCN0000107158) selected for further experiments based on highest Pttg2
silencing efficiency. This clone was modified to express GFP instead of the original
puromycin resistance gene. For lentivirus production, 3 106 293T cells were
seeded onto a 10-cm Petri dish and transfected after 24 h with CalPhos
Mammalian Transfection kit (BD Biosciences Clontech, Palo Alto, CA, USA) using
15mg of the functional construct, 10mg of pCMVDR8.91 and 5mg of pMDG.
Lentivirus were harvested 72 h post-transfection, passed through a 0.45-mm filter,
and concentrated by ultracentrifugation at 22 000 r.p.m. for 90min. Virus particles
were resuspended in cell growth medium and stored at  80 1C. Lentiviral
particles titers were determined by FACS analysis of GFP-positive cells.
For infection with the lentiviral stock, HCT116 cells were seeded 24 h prior to
infection and then the lentiviral particles were added (MOI¼ 10 for Pttg1 and
MOI¼ 5 for Pttg2).
Production and purification of recombinant proteins. To produce
a glutathione S-transferase (GST)-PTTG2 fusion protein, the Pttg2 ORF
containing BamHI and EcoRI flanking sites was subcloned into the BamHI and
EcoRI sites of the pRSET vector (Invitrogen) or into the pGEX4-T (Amersham,
Piscataway, NJ, USA) for the production of His-tagged or GST-tagged proteins,
respectively. The GST fusion proteins were expressed in Escherichia coli BL21
codon plus (Stratagene, La Jolla, CA, USA) and purified as described.37 For the
purification of His-tagged proteins, cells were induced with 1-mM IPTG for 3 h at
37 1C and harvested. The cell pellet was resuspended in 1/25 of the bacterial
culture volume in buffer (50mM sodium phosphate pH 7.5, 300mMNaCl, 0.5%
Sarkosyl, 1 mM PMSF and 1 protease inhibitor cocktail) and incubated for 15min
on ice. Just before sonication 20% Triton was added. Cell lysates were cleared by
centrifugation at 15 000 r.p.m. for 30min and incubated with TALON metal affinity
resin (BD Biosciences Clontech) beads (GE Healthcare, Madrid, Spain) overnight
at 4 1C. Beads were washed three times with 10 volumes of lysis buffer lacking the
protease inhibitor cocktail. Yield and purity of all recombinant proteins were
assessed by 10% SDS-PAGE and Coomassie staining. Protein concentrations
were determined using a BSA standard.
Anti-pttg2 antibody production. To generate anti-PTTG2 antibodies,
recombinant GST-fused or His-tagged PTTG2 cDNA (ORF) was produced in
E. coli and purified on glutathione-agarose beads (Sigma) and TALON His-Tag
purification resin (BD Biosciences Clontech), respectively. Alternatively, antibodies
were made against a synthetic peptide located at the C-terminus of PTTG2 protein
(amino-acid sequence CNLFAVSFKHSVDPG). Rabbit polyclonal antibodies
against PTTG2 were affinity-purified by absorption of the sera to His or
GST-fused PTTG2 protein immobilized onto CNBr-activated Sepharose
(GE Healthcare) and elution at high pH or using the SulfolinkImmobilization Kit
for Peptides (Pierce, Rockford, IL, USA).
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Western blot analysis. Protein expression was determined by immunoblotting
using the following specific antibodies. The human polyclonal rabbit
Pttg1 antibody was generated as described8 and used at 1 : 2000 dilution.
Monoclonal antibodies against a-tubulin, acetylated-a-tubulin, FLAG and b-actin were
purchased from Sigma and anti-p53 (DO1), anti-myc and anti-GAPDH from Santa
Cruz, CA, USA. The polyclonal antibodies against active, cleaved caspase-3 were
obtained from Cell Signaling (Boston, MA, USA) and against p21 and E-cadherin
from Santa Cruz and Beckton Dickinson, respectively. Protein levels were normalized
to b-actin or GAPDH expression. Cell lysates were prepared using radio-
immunoprecipitation assay (RIPA) buffer (150mmol/l NaCl, 50mmol/l Tris (pH 8.0),
0.5% deoxycholic acid, 1% NP40, 0.1% SDS and 1 protease cocktail inhibitor
(Roche, Basel, Switzerland). Protein content was quantified using Bradford (Bio-Rad,
Madrid, Spain). Fold change in specific protein expression was determined on the
basis of b-actin or GAPDH expression as a loading control.
Quantitative RT-PCR (qRT-PCR). Cells were seeded and infected with
control or shPttg2lentivirus for 72 h. Total RNA was prepared using TRIZOL
reagent (Invitrogen) followed by treatment with TURBO DNase (Ambion, Austin,
TX, USA). RT-PCR experiments were carried out using 1 ml of cDNAs generated
from 1 mg of total RNA using Supersript III (Invitrogen). Expression of human
Pttg1, Pttg2 and Pttg3 expression was determined using the Applied Biosystems
7500 Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). To
determine human Pttg1 mRNA levels, we used two Pttg1 sequence-specific PCR
primers and a FAM-labeled probe obtained from Operon Biotechnologies
(Ebersberg, Germany) (Supplementary Table S1). Expression of Pttg2 and Pttg3
was measured using the Applied BiosystemsTaqMan Gene Expression Assays
Hs00747713_sH and Hs00607485_s1. Reactions were carried out at 50 1C for
2min, 95 1C for 10min followed by 40 cycles of 95 1C for 15 s and 60 1C for 1min.
The levels of E-cadherin and Vimentin were analyzed using the primers indicated
in Supplementary Table S138 and SYBR green master mix (Applied Biosystems).
The expression of human hprt1 gene was used to normalize variations in cDNA
quantities from different samples.
Immunocytochemistry. Cells grown on coverslips were fixed with methanol
at  20 1C for 6 min or 4% paraformaldehyde/phosphate-buffered saline at room
temperature for 15min. After fixation, the coverslips were incubated with primary
antibodies as indicated. Species-specific secondary antibodies conjugated with
AlexaFluor488, AlexaFluor546 and AlexaFluor633 (Invitrogen) were used. Nuclei
were labeled with 40-6-diamidino-2-phenylindole (DAPI) (200 ng/ml). Wide-field
fluorescence imaging was performed using a LeicaDM6000B microscope (Leica,
Wetzlar, Germany). Confocal images were captured using a Leica TCS SP5
microscope and HCX PL APO Lambda blue 63 1.4 oil objective. Images were
analyzed using LAS AF (Leica) and Adobe Photoshop software (Adobe Systems
Iberica, Barcelona, Spain).
Immunoprecipitations. For immunoprecipitations, 3 106 HEK293T cells
were seeded onto a 60-mm Petri dish and transfected with Lipofectamine 2000
(Invitrogen) with plasmids as indicated. After 24 h, cells were lysed in NP40 lysis
buffer (100mMNaCl, 20mM Tris-HCl pH 7.5, 5% glycerol, 1mM EDTA pH 8, 1mM
MgCl2 and 0.1–0.5% NP40 with 1mM PMSF and 1 protease cocktail inhibitor
from Roche). Cellular lysated were precleared with magnetic Dynabeads protein A
for 1 h at 4 1C. After magnetic separation, beads were discarded and supernatants
incubated overnight at 4 1C with monoclonal antibodies as indicated or protein A
followed by beads for 2 h. Beads were washed five times with lysis buffer and
bound proteins were dissolved into SDS sample buffer at 95 1C for 5 min and
subjected to SDS-PAGE and analyzed by western blot.
Luciferase-based transactivation assays. Cells were seeded in
24-well plates at a density of 105 cells/well and allowed to reach 60–70%
confluence and transfected with Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions. After 24 h, cells were lysed and the luciferase activity
was assayed in the lysates using Promega’s Dual-luciferase assay system
according to the manufacturer’s protocol (Promega, Madrid, Spain). Values are
normalized to the ratio of Renilla to firefly luciferase activity in the mock-
transfected cells.
Cell-cycle analysis. Cell-cycle distribution was determined by propidium
iodide staining. Cells were cultured under experimental conditions and harvested
by first detaching adherent cells with trypsin and washing the cells with PBS. Cells
were fixed by resuspension in 1ml 70% ethanol and incubated at 4 1C overnight.
Fixed cells were stained in 100 ml PBS containing 50mg/ml PI (Sigma) and
250mg/ml RNAse. Samples were incubated for at least 30min at 37 1C before
being analyzed by flow cytometry.
BrdU staining. Cells were pulsed with 30mM BrdU (Sigma) for 30min, fixed in
70% ethanol, and incubated with PE-conjugated anti-BrdU antibody
(BD Biosciences). DNA was then stained using 7-AAD (BD Biosciences) and
cellular fluorescence was determined using FACS calibur flow cytometer (Becton
Dickinson, Madrid, Spain). Data were analyzed using CellQuest-Pro 5.2.1 software
(Becton Dickinson).
Mitotic index. To increase the number of cells in mitosis, HCT116 cells were
treated with Nocodazole (Sigma) at 1mM for 24 h, fixed in 70% ethanol and
incubated with primary anti-phospho-histone H3 antibody (Millipore, Bedford, MA,
USA) at 1 : 200 dilution at room temperature for 2 h, and then with Cy3-conjugated
goat anti-rabbit secondary antibody at 1 : 200 dilution for 1 h at room temperature
in the dark. DNA was then stained using 7-AAD (BD Biosciences) and cellular
fluorescence was determined using FACS calibur flow cytometer (Becton
Dickinson). Data were analyzed using CellQuest-Pro 5.2.1 software.
Microarray-based gene expression analysis. Cells were seeded and
infected with control or shPttg2lentivirus for 72 h. Total RNA was extracted from
both groups of cells using the guanidiniumisothiocynate method (TRIzol reagent;
Invitrogen) followed by TURBODNasetreatment (Ambion). The isolated RNA was
quantified by a NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE,
USA). RNA quality was assessed by using the Agilent Model 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA). An aliquot (300 ng) of the total RNA
was subjected to an AffymetrixGeneChip Human Gene 1.0 ST Array (genome-
wide expression profiling chip, 28.869 genes, Affymetrix, Santa Clara, CA, USA)
according to the GeneChip Whole Transcript (WT) Sense Target Labeling Assay
manual as previously reported.39,40 After the hybridization of the labeled single-
strand cDNAs produced from the total RNAs to the GeneChips, the chips were
scanned using a Fluidics 450 station and GeneChip Operating Software
(Affymetrix). The quality control of the cDNA synthesis, labeling and hybridization
process was verified to be optimal. Statistical analysis was based in data
normalization and ANOVA (including t-tests) and was used to identify differentially
expressed genes.
Gene ontology analysis. The differently expressed probe sets were
analyzed with GO terms, which describe the functional attributes of a gene product
in each of these three categories: molecular function, biological process and
cellular component. The DAVID version 6.7 software provides statistical analyses
in each of the three categories. One-sample two-sided binomial test was used to
identify which GO terms of a particular population of probe sets had a significantly
different proportion from the overall population (Po0.05). The resulting significant
GO terms were manually organized and simplified usually with the help of the
hierarchy annotated at the GO database (www.geneontology.org).
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